Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. To ...

Prasugrel is associated with lower rates of mortality, myocardial infarction (MI), and stroke than ticagrelor under conditions of routine care of patients discharged after invasive treatment for acute ...

Prasugrel (Efient, Eli Lilly and Company/Daiichi-Sankyo) is an oral inhibitor of platelet activation and aggregation. It works by the irreversible binding of its active metabolite to the P2Y12 class ...

Both ticagrelor and prasugrel show evidence of a delay in the onset of antiplatelet action in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary ...

What does this mean for me? If you have acute coronary syndrome and are having a procedure called percutaneous coronary intervention, and your doctor thinks that prasugrel is the right treatment, you ...